Literature DB >> 12727811

Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice.

Paul J Grippo1, Patrick S Nowlin, Michael J Demeure, Daniel S Longnecker, Eric P Sandgren.   

Abstract

Activating mutation of the Kras oncogene is the most frequent and perhaps the earliest genetic alteration associated with pancreatic cancer. To examine the link between mutant Kras and exocrine pancreatic cancer, we generated transgenic mice carrying an elastase-mutant Kras transgene, which targets expression to pancreatic acinar cells. Most elastase-Kras founder mice displayed perinatal pancreatic acinar cell hyperplasia and dysplasia. However, adult mice in two surviving lineages displayed preinvasive pancreatic neoplastic lesions with ductal morphology, thereby providing a unique mouse model in which lesion histotype and initiating genetic alteration overlap with the human disease. Our findings suggest that Kras mutation is associated with development of early stage duct-like lesions in pancreas, but that additional alterations must accompany progression to malignancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727811

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  93 in total

1.  Alteration of strain background and a high omega-6 fat diet induces earlier onset of pancreatic neoplasia in EL-Kras transgenic mice.

Authors:  Eric C Cheon; Matthew J Strouch; Morgan R Barron; Yongzeng Ding; Laleh G Melstrom; Seth B Krantz; Bhargava Mullapudi; Kevin Adrian; Sambasiva Rao; Thomas E Adrian; David J Bentrem; Paul J Grippo
Journal:  Int J Cancer       Date:  2010-10-26       Impact factor: 7.396

Review 2.  Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.

Authors:  Lawrence M Knab; Paul J Grippo; David J Bentrem
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.

Authors:  Chanjuan Shi; Seung-Mo Hong; Phillip Lim; Hirohiko Kamiyama; Mehtab Khan; Robert A Anders; Michael Goggins; Ralph H Hruban; James R Eshleman
Journal:  Mol Cancer Res       Date:  2009-02-10       Impact factor: 5.852

4.  RPL38, FOSL1, and UPP1 are predominantly expressed in the pancreatic ductal epithelium.

Authors:  Fikret Sahin; Wanglong Qiu; Robb E Wilentz; Christine A Iacobuzio-Donahue; Andres Grosmark; Gloria H Su
Journal:  Pancreas       Date:  2005-03       Impact factor: 3.327

Review 5.  Metaplasia: tissue injury adaptation and a precursor to the dysplasia-cancer sequence.

Authors:  Veronique Giroux; Anil K Rustgi
Journal:  Nat Rev Cancer       Date:  2017-09-01       Impact factor: 60.716

6.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

7.  The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer.

Authors:  Brian C Lewis; David S Klimstra; Harold E Varmus
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

8.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

Review 9.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

10.  Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling.

Authors:  Jean-Paul De La O; L Charles Murtaugh
Journal:  Cell Cycle       Date:  2009-06-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.